

NOTIFICATION OF PARTICIPATION AND FORM FOR POSTAL VOTING

in accordance with § 8 of Swedish Orphan Biovitrum AB (publ)'s Articles of Association.

To be received by Euroclear Sweden AB no later than 9 August 2023.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, at the Extraordinary General Meeting on 15 August 2023. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this postal vote on behalf of the shareholder and that the contents of the postal vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions:

- Complete the information above.
- Select the preferred voting options below.
- Print, sign and send the form to Swedish Orphan Biovitrum AB (publ), “Extraordinary General Meeting”, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in such case, be sent to generalmeetingservice@euroclear.com. Shareholders may also cast their votes electronically through verification with BankID via Euroclear Sweden AB’s website <https://anmalan.vpc.se/euroclearproxy?sprak=1>.
- If the shareholder is a natural person who is personally voting by post, it is the shareholder who should sign under *Signature* above. If the postal vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the postal vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- If the shareholder submits its postal vote by proxy, a power of attorney must be enclosed with the postal voting form. Powers of attorney in Swedish and in English are available on the company’s website www.sobi.com and also upon request. If the shareholder is a legal entity, a registration certificate or corresponding document must be enclosed with the form.
- **Please note that a shareholder whose shares are registered in the name of a bank or other nominee must register its shares in its own name to vote.** Instructions regarding this are included in the notice convening the meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the postal vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The postal voting form, together with any enclosed authorisation documentation, shall be received by Euroclear Sweden AB no later than 9 August 2023. A postal vote can be withdrawn up to and including 9 August 2023 by contacting Euroclear Sweden AB at e-mail generalmeetingservice@euroclear.com. Shareholders who have cast their postal votes electronically through verification with BankID may also withdraw their postal vote at <https://anmalan.vpc.se/euroclearproxy>.

A shareholder who has voted by post may also attend the meeting venue, provided that notice of participation to attend the meeting venue has been made in accordance with the instructions stated in the notice convening the Extraordinary General Meeting. If the shareholder has submitted its postal vote and thereafter attends the meeting venue in person or by proxy, the postal vote will still be valid, provided that the shareholder does not participate in a voting during the meeting or otherwise withdraws its submitted postal vote. If the shareholder chooses to participate in a voting during the meeting, the vote cast at the meeting will replace the previously submitted postal vote with regard to the relevant decision(s). **Please note that the postal vote does not constitute a notice of participation to attend the meeting venue in person or by proxy.**

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the Extraordinary General Meeting and the company’s website www.sobi.com.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear Sweden AB’s website, <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) on 15 August 2023

The voting options below comprise the proposals submitted by the Board of Directors included in the notice convening the Extraordinary General Meeting.

2. Election of the chairman of the Meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
3. Preparation and approval of the voting list Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination of whether the Meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
7. Resolution regarding authorisation of the Board of Directors to resolve on new issue of common shares Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Resolution regarding I. authorisation of the Board of Directors to resolve on a directed issue of series C shares and II. authorisation of the Board of Directors to resolve on repurchase of issued series C shares Yes <input type="checkbox"/> No <input type="checkbox"/>